

Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:


Listing of Claims:

Claims 1-25: Cancelled.


Claim 26 (Previously presented): A compound which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713 cm^{-1} .

Claim 27 (Currently Amended): A compound which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides ~~[[the]]~~ an X-ray powder diffraction pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 $^{\circ}2\theta$.

Claim 28 (Currently Amended): A compound which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound, in a mineral oil dispersion, provides an infra red spectrum substantially in accordance with Figure [[F]] 1:



Claim 29 (Currently Amended): A compound which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides an X-ray powder diffraction pattern substantially in accordance with the Figure [[H]] 2:



Claim 30 (Previously presented): A compound which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides:

- (i) an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713 cm^{-1} ; and
- (ii) an X-ray powder diffraction pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 $^{\circ}2\theta$.

Claim 31 (Previously presented): A process for preparing the compound according to any one of claims 26-30, comprising treating 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione with aqueous hydrochloric acid.

Claim 32 (Previously presented): The process according to claim 31, further comprising treating 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in aqueous propan-2-ol with aqueous hydrochloric acid at a temperature in the range of 60°C-80°C.

Claim 33 (Previously presented): A pharmaceutical composition comprising an effective, non-toxic amount of the compound according to any one of claims 26-30 and a pharmaceutically acceptable carrier therefore.

Claims 34-35 (Cancelled).

Claim 36 (Previously presented): A method for the treatment of Type II diabetes mellitus in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the compound according to any one of claims 26-30 to a human or non-human mammal in need thereof.

Claim 37 (Previously presented): A tablet or capsule comprising an effective, non-toxic amount of the compound according to any one of claims 26-30 and a pharmaceutically acceptable carrier therefore.